We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+2.7%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.5B
AUM Growth
-$430M
Cap. Flow
-$140M
Cap. Flow %
-9.32%
Top 10 Hldgs %
47.39%
Holding
116
New
31
Increased
19
Reduced
31
Closed
29

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$31.2M
2
OGN icon
Organon & Co
OGN
+$23M
3
CYH icon
Community Health Systems
CYH
+$19.2M
4
RCM
R1 RCM Inc. Common Stock
RCM
+$18.6M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$17.3M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$71.3M
2
GSK icon
GSK
GSK
+$28.4M
3
TGTX icon
TG Therapeutics
TGTX
+$27.2M
4
ELV icon
Elevance Health
ELV
+$20.5M
5
CTLT
CATALENT, INC.
CTLT
+$17.2M

Sector Composition

Rank Sector Weight
1 Healthcare 65.27%
2 Miscellaneous 33.54%
3 Industrials 1.14%
4 Financials 0.05%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$107M 7.13%
250,000
+150,000
+150% +$62.6M
QQQ icon
2
PUT
Invesco QQQ Trust
QQQ
$489B
$88.6M 5.91%
+250,000
New +$84.1M
UTHR icon
3
United Therapeutics
UTHR
$22.1B
$79.5M 5.3%
442,945
-43,584
-9% -$8.3M
AMRN
4
Amarin Corp
AMRN
$295M
$73M 4.87%
833,474
-11,366
-1% -$1.12M
ARKG icon
5
ARK Genomic Revolution ETF
ARKG
$1.88B
$71.5M 4.77%
773,480
-33,452
-4% -$2.84M
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$62.4M 4.16%
666,738
-28,721
-4% -$2.64M
AZN icon
7
AstraZeneca
AZN
$252B
$59M 3.94%
492,861
-3,297
-0.7% -$362K
CYH icon
8
Community Health Systems
CYH
$413M
$59M 3.93%
3,821,729
+1,415,895
+59% +$19.2M
GSK icon
9
CALL
GSK
GSK
$102B
$55.9M 3.73%
1,122,960
+199,680
+22% +$9.59M
DHR icon
10
Danaher
DHR
$152B
$55M 3.66%
230,907
+30,649
+15% +$6.8M
XLRN
11
DELISTED
Acceleron Pharma
XLRN
$42M 2.8%
335,045
+93,064
+38% +$11.7M
BIIB icon
12
CALL
Biogen
BIIB
$32.3B
$40M 2.67%
+115,600
New +$35M
TEVA icon
13
Teva Pharmaceuticals
TEVA
$42.5B
$37.7M 2.51%
3,804,405
-550,351
-13% -$5.83M
VRTX icon
14
CALL
Vertex Pharmaceuticals
VRTX
$137B
$34.9M 2.33%
173,300
+113,300
+189% +$23.7M
AVTR icon
15
Avantor
AVTR
$9.86B
$34.6M 2.31%
974,637
+15,650
+2% +$506K
BMY icon
16
Bristol-Myers Squibb
BMY
$136B
$32M 2.13%
+478,328
New +$31.2M
ASND icon
17
Ascendis Pharma A/S
ASND
$16.3B
$31.8M 2.12%
241,774
-70,093
-22% -$9.34M
QGEN icon
18
Qiagen
QGEN
$8.9B
$31.5M 2.1%
613,962
+185,135
+43% +$9.56M
FATE icon
19
Fate Therapeutics
FATE
$291M
$30.1M 2%
346,347
+24,587
+8% +$1.98M
OCDX
20
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
$29.9M 1.99%
1,394,284
+19,056
+1% +$387K
AMRX icon
21
Amneal Pharmaceuticals
AMRX
$6.11B
$28.8M 1.92%
5,624,725
+869,245
+18% +$4.94M
NVST icon
22
Envista
NVST
$4.36B
$28.3M 1.89%
656,098
-76,586
-10% -$3.32M
XBI icon
23
CALL
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$27.1M 1.8%
+200,000
New +$26.3M
OGN icon
24
Organon & Co
OGN
$3.61B
$21.2M 1.41%
+699,696
New +$23M
ARKG icon
25
CALL
ARK Genomic Revolution ETF
ARKG
$1.88B
$18.4M 1.23%
+199,000
New +$16.9M
1
2 3 4 5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2021 Portfolio in Review

As of Q2 2021, Eversept Partners held 116 positions worth $1.5B, down 22% from $1.93B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Eversept Partners withdrew a net $140M in Q2 2021, closing 29 positions and reducing 31 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $71.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 59% a quarter earlier, followed by Miscellaneous and Industrials.

Against the trend, Eversept Partners opened a new position in Bristol-Myers Squibb worth $32M.

  • Eversept Partners's largest Q2 2021 buy was Bristol-Myers Squibb: 478,328 shares worth $32M.
  • Eversept Partners added most to Community Health Systems in Q2 2021, an estimated $19.2M increase.
  • Eversept Partners's biggest Q2 2021 reduction was GSK, cutting an estimated $28.4M.
  • Eversept Partners fully exited Alexion Pharmaceuticals in Q2 2021, selling an estimated $71.3M.
  • Eversept Partners's ten largest holdings make up 47% of its $1.5B portfolio in Q2 2021.
  • Eversept Partners opened 31 new positions and closed 29 in Q2 2021.
  • Eversept Partners's portfolio value fell 22% quarter-over-quarter to $1.5B.

Based on Eversept Partners's 13F filing for Q2 2021, filed 16 Aug 2021.